MERGA DIVISION
Pentinus® SR 300 Neurology & Neuropathic Pain
PRODUCT OVERVIEW
About PENTINUS® SR 300
PENTINUS® SR 300 is positioned within the neurology portfolio of Seginus Pharma’s MERGA Division. Its formulation characteristics, appropriate use and clinical suitability should be evaluated against the approved product information by qualified healthcare professionals.
PRODUCT OVERVIEW
About PENTINUS® SR 300
PENTINUS® SR 300 is positioned within the neurology portfolio of Seginus Pharma’s MERGA Division. Its formulation characteristics, appropriate use and clinical suitability should be evaluated against the approved product information by qualified healthcare professionals.
Composition & Therapeutic Profile
PENTINUS® SR 300 reflects Seginus Pharma’s commitment to specialty-focused pharmaceutical solutions and responsible neurological care.
Composition
Gabapentin 300 mg
Therapeutic Class
Neurological medicine with anticonvulsant activity.
Therapeutic Focus
Selected neuropathic pain and seizure-related indications, where approved.
How Gabapentin Works
Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the nervous system.
This action can reduce the release of certain excitatory neurotransmitters involved in neuronal signalling, contributing to its therapeutic activity in approved neurological indications.
Calcium Channel Binding
Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the nervous system.
Neurotransmitter Modulation
Its activity influences the release of certain excitatory neurotransmitters involved in neuronal signalling.
Neuronal Signal Regulation
These actions contribute to gabapentin’s pharmacological effects in approved neurological indications.
Clinical & Therapeutic Areas
PENTINUS® SR 300 is positioned within key neurological care areas, with its clinical application guided by approved indications, individual patient needs and healthcare professional assessment.
Neuropathic Pain
Use in approved neuropathic pain conditions, as specified in the product information.
Seizure-Related Conditions
Adjunctive treatment for selected seizure disorders where approved.
Individualised Care
Treatment decisions based on clinical assessment, renal function and tolerability.
Frequently Asked Questions
The supplied image identifies it as gabapentin extended-release tablets 300 mg.
No. Gabapentin is used for selected conditions; suitability depends on diagnosis and the approved label.
Do not stop or change the dose without medical advice. A clinician may recommend gradual dose reduction depending
on the indication and duration of use.
Discover Our Specialty Pharmaceutical Portfolio
Explore the MERGA and PRINCEPS divisions of Seginus Pharma and discover our portfolio of pharmaceutical products across key therapeutic areas.
